{
  "guideline": {
    "id": "PA166265161",
    "name": "Annotation of DPWG Guideline for carbamazepine and HLA-A",
    "source": "DPWG",
    "version": 11,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166265161",
    "relatedChemicals": [
      {
        "id": "PA448785",
        "name": "carbamazepine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA35055",
        "name": "major histocompatibility complex, class I, A",
        "symbol": "HLA-A"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166299111",
      "name": "Recommendation PA166299111",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA448785",
          "name": "carbamazepine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061474,
        "html": "<ul>\n<li>\n<p>Carefully weigh the risk of DRESS and SJS/TEN against the benefits</p>\n</li>\n<li>\n<p>If an alternative is an option, choose an alternative</p>\n</li>\n</ul>\n"
      },
      "implications": [
        "Patients with this genetic variation have an increased risk of experiencing the life-threatening cutaneous adverse events DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN). The risk of carbamazepine-induced DRESS in these patients is 0.89%."
      ],
      "lookupKey": {
        "HLA-A": "*31:01 positive"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [],
  "version": "2024-03-25-16-13"
}